NASDAQ:GBIO - Nasdaq - US37148K1007 - Common Stock - Currency: USD
GBIO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. GBIO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, GBIO is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -35.72% | ||
ROE | -98.09% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -5.1 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8.43 | ||
Quick Ratio | 8.43 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
0.38
+0 (+1.17%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 1.04 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.35 | ||
P/tB | 0.35 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -35.72% | ||
ROE | -98.09% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 15.33% | ||
Cap/Sales | 2.97% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 8.43 | ||
Quick Ratio | 8.43 | ||
Altman-Z | -5.1 |